Liraglutide and cardiovascular outcomes in type 2 diabetes

New England Journal of Medicine

Volumn 375, Issue 4, 2016, Pages 311-322

  Marso, Steven P ^a   Daniels, Gilbert H ^b   Frandsen, Kirstine Brown ^c   Kristensen, Peter ^c   Mann, Johannes F E ^d   Nauck, Michael A ^e   Nissen, Steven E ^f   Pocock, Stuart ^g   Poulter, Neil R ^h   Ravn, Lasse S ^c   Steinberg, William M ⁱ   Stockner, Mette ^c   Zinman, Bernard ^j   Bergenstal, Richard M ^k   Buse, John B ^l  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e ST JOSEF HOSPITAL   (Germany)

^f LERNER RESEARCH INSTITUTE   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^j MOUNT SINAI HOSPITAL   (Canada)

^k INTERNATIONAL DIABETES CENTER   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ACUTE PANCREATITIS; ADULT; ALLERGIC REACTION; ARTICLE; BENIGN TUMOR; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CHRONIC PANCREATITIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; FOOT ULCER; GALLSTONE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOTHYROIDISM; INJECTION SITE REACTION; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; RISK FACTOR; SIDE EFFECT; THYROID MEDULLARY CARCINOMA; VOMITING; WEIGHT REDUCTION; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

EID: 84978839381     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1603827     Document Type: Article

References (27)

1. Introduction. Diabetes Care 2016; 39: Suppl 1:S1-2.
2. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation, 2015.
3. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17.
4. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. London: European Medicines Agency, 2012.
5. Guidance for industry: diabetes mel-litus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Department of Health and Human Services, 2008.
6. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipepti-dyl peptidase-4 inhibitors. Diabetes Obes Metab 2016;18:203-16.
7. Du Q, Wang YJ, Yang S, Zhao YY, Han P. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther 2014;31:1182-95.
8. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exena-tide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3.
9. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. Am Heart J 2013; 166(5): 823-30.e5.
10. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.
11. McGuire DK, Van de Werf F, Armstrong PW, et al. Association between si-tagliptin use and heart failure hospital-ization and related outcomes in type 2 diabetes mellitus. JAMA Cardiol 2016; 2: 126-35.10.1001/jamacardio.2016.0103
12. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
13. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-803.
14. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
15. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macro-vascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
16. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319-28.
17. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
18. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35.
19. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
20. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
21. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incre-tin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014; 10: 88-103.
22. Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotec-tion with incretin-based drugs. Kidney Int 2014;86:701-11.
23. Chalmer T, Almdal TP, Vilsbøll T, Knop FK. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes - focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf 2015;14:171-80.
24. Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglu-tide type 2 diabetes clinical trials. Diabetes Care 2015;38:1058-66.
25. Tseng CH, Lee KY, Tseng FH. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2015;33:67-124.
26. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687-99.
27. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86.